Low-density Lipoprotein Levels Are One of the Independent Determinants of Circulating Levels of Advanced Glycation End Products in Nondiabetic Subjects

Overview

Journal Clin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2009 Aug 1

PMID 19645034

Citations 4

Authors

Sho-Ichi Yamagishi

Hisashi Adachi

Takanori Matsui

Kazuo Nakamura

Masayoshi Takeuchi

Mika Enomoto

Ako Fukami

Maki Otsuka

Shun-Ichi Kumagae

Yasuki Nanjo

Shin-Ichiro Ueda

Tsutomu Imaizumi

Affiliations

Soon will be listed here.

Abstract

Background: Nonenzymatic modification of proteins by reducing sugars leads to the formation of advanced glycation end products (AGEs), whose process has been reported to progress under diabetes. Recently, diet has been found to be a major environmental source of proinflammatory AGEs in humans. Further, fats or meat-derived products processed by high heat such as broiling have been shown to contain more AGEs than carbohydrates boiled for longer periods. Since circulating levels of low-density lipoprotein cholesterol (LDL-C) are also regulated by dietary cholesterol, it is conceivable that intake of cholesterol-rich foods could regulate serum levels of AGEs in humans. In this study, we investigated whether LDL-C levels are one of the independent determinants of circulating AGEs levels in a nondiabetic general population.

Methods: A total of 170 nondiabetic Japanese subjects underwent a complete history, physical examination, determination of blood chemistries, and serum AGEs.

Results: Univariate analysis showed that AGEs levels were associated with LDL-C (P < 0.05) and fasting plasma glucose levels (P < 0.05). By the use of multiple stepwise regression analyses, LDL-C (P < 0.01) and fasting plasma glucose levels (P < 0.05) remained significant and were independently related to AGEs levels (R2 = 0.069).

Conclusions: The present study is the first demonstration that LDL-C levels are one of the independent determinants of serum levels of AGEs in a nondiabetic general population. Intake of cholesterol-rich foods may regulate serum levels of AGEs in nondiabetic subjects.

Citing Articles

Effects of Toxic AGEs (TAGE) on Human Health.

Takeuchi M, Sakasai-Sakai A, Takata T, Takino J, Koriyama Y Cells. 2022; 11(14).

PMID: 35883620 PMC: 9317028. DOI: 10.3390/cells11142178.

Toxic AGEs (TAGE) theory: a new concept for preventing the development of diseases related to lifestyle.

Takeuchi M Diabetol Metab Syndr. 2020; 12(1):105.

PMID: 33292465 PMC: 7708159. DOI: 10.1186/s13098-020-00614-3.

Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related Diseases.

Takeuchi M Diagnostics (Basel). 2016; 6(2).

PMID: 27338481 PMC: 4931418. DOI: 10.3390/diagnostics6020023.

Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.

Yamagishi S, Nakamura N, Suematsu M, Kaseda K, Matsui T Mol Med. 2015; 21 Suppl 1:S32-40.

PMID: 26605646 PMC: 4661053. DOI: 10.2119/molmed.2015.00067.

References

Grundy S, Denke M . Dietary influences on serum lipids and lipoproteins. J Lipid Res. 1990; 31(7):1149-72. View

Yamagishi S, Adachi H, Takeuchi M, Enomoto M, Furuki K, Matsui T . Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population. Horm Metab Res. 2007; 39(11):845-8. DOI: 10.1055/s-2007-991176. View

Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y . Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med. 2000; 6(2):114-25. PMC: 1949938. View

Kilhovd B, Juutilainen A, Lehto S, Ronnemaa T, Torjesen P, Birkeland K . High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol. 2005; 25(4):815-20. DOI: 10.1161/01.ATV.0000158380.44231.fe. View

Miura J, Yamagishi S, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z . Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complications. 2002; 17(1):16-21. DOI: 10.1016/s1056-8727(02)00183-6. View

Yamagishi S, Imaizumi T . Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005; 11(18):2279-99. DOI: 10.2174/1381612054367300. View

Brownlee M . Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995; 46:223-34. DOI: 10.1146/annurev.med.46.1.223. View

Lin R, Reis E, Dore A, Lu M, Ghodsi N, Fallon J . Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis. 2002; 163(2):303-11. DOI: 10.1016/s0021-9150(02)00008-4. View

He C, Sabol J, Mitsuhashi T, Vlassara H . Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes. 1999; 48(6):1308-15. DOI: 10.2337/diabetes.48.6.1308. View

10.

Yamagishi S, Nakamura K, Matsui T . Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med. 2007; 7(5):463-9. DOI: 10.2174/156652407781387073. View

11.

Koschinsky T, He C, Mitsuhashi T, Bucala R, Liu C, Buenting C . Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A. 1997; 94(12):6474-9. PMC: 21074. DOI: 10.1073/pnas.94.12.6474. View

12.

Meerwaldt R, Links T, Graaff R, Thorpe S, Baynes J, Hartog J . Simple noninvasive measurement of skin autofluorescence. Ann N Y Acad Sci. 2005; 1043:290-8. DOI: 10.1196/annals.1333.036. View

13.

Saisho Y, Komiya N, Hirose H . Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan. Diabetes Res Clin Pract. 2006; 74(2):201-3. DOI: 10.1016/j.diabres.2006.04.015. View

14.

Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H . Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci. 2005; 1043:461-6. DOI: 10.1196/annals.1333.052. View

15.

Yamagishi S, Nakamura K, Matsui T, Sato T, Takeuchi M . Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. Med Hypotheses. 2005; 66(4):844-6. DOI: 10.1016/j.mehy.2005.08.022. View

16.

Yamagishi S, Ueda S, Okuda S . Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des. 2007; 13(27):2832-6. DOI: 10.2174/138161207781757051. View

17.

Vlassara H, Bucala R, Striker L . Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest. 1994; 70(2):138-51. View

18.

Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K . Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism. 2006; 55(9):1227-31. DOI: 10.1016/j.metabol.2006.05.007. View

19.

Nakamura K, Yamagishi S, Matsui T, Adachi H, Takeuchi M, Imaizumi T . Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin Exp Med. 2008; 7(4):188-90. DOI: 10.1007/s10238-007-0146-7. View